Questions? Feedback? powered by Olark live chat software
Vaccine Innovation

Vaccine Innovation

Vaccine research has long relied on rodents as models for understanding human immune response. Although such models are often useful as a first step in vaccine development, there is increasing evidence that the rodent immune system is markedly different from humans, and that primate model platforms are a more accurate early stage surrogate for human subjects. Preclinical Translational Services offers ready access to several species of well-characterized nonhuman primates, thereby providing an efficient, fast-track approach to vaccine innovation and development.

Because of their many similarities to people, primate models can be more efficient and accurate in providing a one-step, “development to application” strategy for vaccine innovation research. Such an approach can reduce the number of animals needed for studies of efficacy. This one-step strategy is a powerful validation approach that minimizes expenditures by reducing both the time and the number of total animal subjects often required when using rodent models.

Models Available for Testing Vaccine Innovations

  1. Specific pathogen free (SPF) cynomolgus macaques (Macaca fascicularis)
  2. Rhesus monkeys (M. mulatta)
  3. Pedigreed and genomically sequenced African green monkeys (vervets, Chlorocebus aethiops)